Clinical Trial Update: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab, cabozantinib S-malate, and ipilimumab in recurrent stage IV non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non Small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-02-08